Lonox

Acute Chest Syndrome, Deep Vein Thrombosis, Outpatients + 7 more
Treatment
9 FDA approvals
20 Active Studies for Lonox

What is Lonox

EnoxaparinThe Generic name of this drug
Treatment SummaryEnoxaparin is a type of low-molecular-weight heparin (LMWH) used to treat and prevent blood clots. It was approved by the FDA in 1993 and is administered through an injection, either subcutaneously or intravenously. Enoxaparin has been found to be more effective than unfractionated heparin in reducing the risk of venous thromboembolism, while also not increasing the risk of serious bleeding.
Lovenoxis the brand name
image of different drug pills on a surface
Lonox Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Lovenox
Enoxaparin
1993
183

Approved as Treatment by the FDA

Enoxaparin, also known as Lovenox, is approved by the FDA for 9 uses like Prophylaxis of Deep Vein Thrombosis and Acute Coronary Syndrome (ACS) .
Prophylaxis of Deep Vein Thrombosis
Acute Coronary Syndrome (ACS)
Helps manage Acute Coronary Syndrome (ACS)
Deep Vein Thrombosis
Deep Vein Thrombosis
Outpatients
Inpatients
Immobility
Acute Chest Syndrome
Helps manage Acute Coronary Syndrome (ACS)
General Surgery

Effectiveness

How Lonox Affects PatientsEnoxaparin is a drug that works quickly and helps to prevent and reduce blood clots and heart issues. Research has shown that enoxaparin is more effective than heparin at preventing blood clots, and that when taken every 12 hours, it can cause an increase in blood tests (TT and aPTT) by 16%. It is important to be aware that there is an increased risk of bleeding and low blood platelet count when taking enoxaparin, as well as a higher risk of blood clots for pregnant women with artificial heart valves.
How Lonox works in the bodyEnoxaparin is an anticoagulant drug that prevents the formation of blood clots. It works by binding to a molecule called antithrombin III, which stops the formation of an enzyme called factor Xa. This prevents the formation of a clot, which helps to prevent thromboembolic events. Enoxaparin also directly inhibits the enzyme thrombin, though it is less effective than other anticoagulants.

When to interrupt dosage

The suggested dose of Lonox is contingent upon the diagnosed condition, such as Deep Vein Thrombosis, Immobility and Outpatients. The measure additionally fluctuates as indicated by the technique of administration featured in the table beneath.
Condition
Dosage
Administration
Acute Chest Syndrome
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Injection, , Injection - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection - Subcutaneous, Subcutaneous, Solution, Solution - Subcutaneous, Solution - Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, solution
Deep Vein Thrombosis
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Injection, , Injection - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection - Subcutaneous, Subcutaneous, Solution, Solution - Subcutaneous, Solution - Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, solution
Inpatients
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Injection, , Injection - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection - Subcutaneous, Subcutaneous, Solution, Solution - Subcutaneous, Solution - Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, solution
Angioplasty
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Injection, , Injection - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection - Subcutaneous, Subcutaneous, Solution, Solution - Subcutaneous, Solution - Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, solution
Myocardial Infarction
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Injection, , Injection - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection - Subcutaneous, Subcutaneous, Solution, Solution - Subcutaneous, Solution - Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, solution
Immobility
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Injection, , Injection - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection - Subcutaneous, Subcutaneous, Solution, Solution - Subcutaneous, Solution - Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, solution
General Surgery
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Injection, , Injection - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection - Subcutaneous, Subcutaneous, Solution, Solution - Subcutaneous, Solution - Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, solution
Ischemia
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Injection, , Injection - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection - Subcutaneous, Subcutaneous, Solution, Solution - Subcutaneous, Solution - Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, solution
Angina, Unstable
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Injection, , Injection - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection - Subcutaneous, Subcutaneous, Solution, Solution - Subcutaneous, Solution - Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, solution
Outpatients
, 400.0 mg/mL, 600.0 mg/mL, 800.0 mg/mL, 300.0 mg/mL, 100.0 mg/mL, 1200.0 mg/mL, 150.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 900.0 mg/mL
Injection, , Injection - Intravenous; Subcutaneous, Intravenous; Subcutaneous, Injection - Subcutaneous, Subcutaneous, Solution, Solution - Subcutaneous, Solution - Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, Injection, solution

Warnings

Lonox has six contraindications and should not be taken simultaneously with the ailments noted in the subsequent table.Lonox Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Heparin Induced Thrombocytopenia (HIT)
Do Not Combine
Hemorrhage
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Low Platelet Count
Do Not Combine
There are 20 known major drug interactions with Lonox.
Common Lonox Drug Interactions
Drug Name
Risk Level
Description
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Enoxaparin.
Andexanet alfa
Major
The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Enoxaparin.
Anti-inhibitor coagulant complex
Major
The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Enoxaparin.
Antihemophilic factor (recombinant), PEGylated
Major
The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Enoxaparin.
Antihemophilic factor human
Major
The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Enoxaparin.
Lonox Toxicity & Overdose RiskThe lowest toxic dose of enoxaparin in mice is greater than 5000mg/kg if given orally and greater than 2500mg/kg if given subcutaneously. If someone has an accidental overdose of enoxaparin, they may experience bleeding. To counteract the overdose, a 1% protamine sulfate solution should be used intravenously in an amount equal to that of the enoxaparin dose. However, if at least 12 hours have passed since the last enoxaparin dose, protamine may not be necessary. It is important to not give too much protamine as it can be fatal.
image of a doctor in a lab doing drug, clinical research

Lonox Novel Uses: Which Conditions Have a Clinical Trial Featuring Lonox?

76 active clinical trials are currently underway to assess the potential of Lonox in providing relief from Immobility, Acute Chest Syndrome and Outpatient Care.
Condition
Clinical Trials
Trial Phases
Immobility
0 Actively Recruiting
General Surgery
2 Actively Recruiting
Not Applicable
Outpatients
0 Actively Recruiting
Deep Vein Thrombosis
9 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 4
Inpatients
2 Actively Recruiting
Phase 2, Not Applicable
Acute Chest Syndrome
2 Actively Recruiting
Not Applicable, Phase 2
Ischemia
0 Actively Recruiting
Angina, Unstable
0 Actively Recruiting
Myocardial Infarction
0 Actively Recruiting
Angioplasty
6 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 4

Lonox Reviews: What are patients saying about Lonox?

5Patient Review
2/6/2009
Lonox for Diarrhea
While I still sometimes get episodes of IBS, this medication has helped to slow them down and reduce the frequency with which they occur.
5Patient Review
8/21/2008
Lonox for Diarrhea
This drug completely changed my life for the better. I was diagnosed with west nile virus and within a month or two, I could barely leave my house because of how often I needed to use the restroom. This medication allowed me to live a normal life again and I will forever be grateful.
5Patient Review
7/29/2008
Lonox for Diarrhea
I was diagnosed with ulcerative colitis and, as a result, have to deal with diarrhea for the rest of my life. Lonox has been an absolute godsend; it's cut down my "bathroom time" significantly.
5Patient Review
6/23/2009
Lonox for Diarrhea
This pill has been an absolute life-changer for me. I no longer have to worry about finding a bathroom when I'm away from home or risk having an accident.
5Patient Review
4/6/2008
Lonox for Diarrhea
For someone who has dealt with IBS for over a decade, this medication is truly a lifesaver. It's helped to regulate my bowel movements so that instead of going all day long, I only have to go in the morning.
5Patient Review
10/15/2010
Lonox for Diarrhea
These pills have been a wonder for my chronic diarrhea. I'm HIV+ and also have Hep C, so this has been a huge help in managing my symptoms and living a somewhat normal life.
5Patient Review
2/10/2012
Lonox for Diarrhea
This is the only medication that has been effective in treating my diarrhea.
5Patient Review
10/17/2007
Lonox for Diarrhea
4.7Patient Review
12/12/2009
Lonox for Diarrhea
This medication has been extremely helpful in managing my IBS and possible Crohn's disease. It allows me to have a much better quality of life by being able to leave the house without worry.
4Patient Review
11/24/2007
Lonox for Diarrhea
3.3Patient Review
8/8/2009
Lonox for Diarrhea
I experienced some pretty intense side effects when I first started taking this medication. dizziness, blurred vision, and nausea were all common for me. I discontinued use after only five days. It took a full three weeks for the medicine to completely clear out of my system.

Patient Q&A Section about lonox

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Lonox used for?

"This medication is used to treat diarrhea. It helps to decrease the number and frequency of bowel movements by slowing the movement of the intestines. Diphenoxylate is similar to opioid pain relievers, but it acts mainly to slow the gut."

Answered by AI

Does diphenoxylate Atrop get you high?

"However, when diphenoxylate is taken in high doses, it can cause euphoria and physical dependence like other narcotics. To prevent people from abusing diphenoxylate for its mood-elevating effects, atropine is added to it in small quantities."

Answered by AI

What is diphenoxylate used to treat?

"Diphenoxylate and atropine combination is used to treat severe diarrhea, along with other measures such as fluid and electrolyte treatment. Diphenoxylate helps to stop diarrhea by slowing down the movements of the intestines."

Answered by AI

Is Lonox a controlled substance?

"A healthcare provider may prescribe Lomotil for diarrhea associated with irritable bowel syndrome (IBS) or other digestive diseases or conditions. Lomotil is a controlled substance and is chemically related to a narcotic."

Answered by AI

Clinical Trials for Lonox

Image of Children's Hospital Colorado in Aurora, United States.

Facility Dog for Anxiety in Children

8 - 17
All Sexes
Aurora, CO
The goal of this clinical trial is to learn if medical dog intervention facilitated by a Certified Child Life Specialist (CCLS) impacts pediatric patient coping, fear, and anxiety during inpatient admissions. The main questions it aims to answer are: What impact does facility dog support via a CCLS have on patient fear, coping, and anxiety? What effect does facility dog support via a CCLS have on patient heart rate? Researchers will compare medical dog intervention facilitated by a CCLS, CCLS intervention, and a coloring activity to see if medical dog interventions positively impact coping, fear, and anxiety. Participants will: Receive a visit from a medical dog and their CCLS handler, a CCLS, or a Child Life Activity coordinator. Engage in a mindfulness or coloring activity. Answer surveys regarding anxiety, coping, and fear. Have their heart rate measured before, during, and after their assigned intervention.
Waitlist Available
Has No Placebo
Children's Hospital ColoradoSarah Scott
Image of Baystate Medical Center in Springfield, United States.

Consent Approaches for Heart Disease Rehabilitation

18+
All Sexes
Springfield, MA
Cardiac Rehabilitation is a lifestyle and exercise program for patients with heart disease. Cardiac Rehabilitation is strongly recommended in guidelines, but only 30% of eligible patients attend. New strategies are needed to help more patients attend cardiac rehabilitation. In this study, the investigators will see if using an $50 incentive, case management, text messages, and physical activity coaching combined into a single intervention will help more patients attend cardiac rehabilitation. In preparation for a larger trial, patients will also be randomly assigned to four different ways of seeking their permission to be in a research study. The investigators will see if these approaches affect how many people participate in the research project. The two main goals of this study is to understand: 1. If the consent approach type impacts participation rates in the research study 2. If the multi-component intervention (case management, financial incentives, text messages, and physical activity coaching) improves cardiac rehabilitation participation within 3 months.
Waitlist Available
Has No Placebo
Baystate Medical CenterQuinn R Pack, MD, MSc
Image of Abcentra Investigational Site in Los Angeles, United States.

Orticumab for Heart Attack

18+
All Sexes
Los Angeles, CA
The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies
Phase 2
Recruiting
Abcentra Investigational Site (+6 Sites)Abcentra
Have you considered Lonox clinical trials? We made a collection of clinical trials featuring Lonox, we think they might fit your search criteria.Go to Trials
Image of St. Paul's Hospital in Vancouver, Canada.

Enhanced Vitals Monitoring for Surgery

18+
All Sexes
Vancouver, Canada
The aim of this clinical trial is to examine the feasibility of an enhanced vital sign monitoring solution in-hospital and at-home. This study includes adult patients undergoing inpatient major vascular or abdominal surgery. Researchers will compare the enhanced vitals monitoring group to the standard of care group to see if it may change post-operative management and outcomes. The primary question it aims to answer is if enhanced monitoring of surgical patient vitals can increase the number of days at home alive in the first 30 days after surgery. Participants in the intervention group will test two vitals monitoring devices, one in the hospital and one at home. They will also be asked to complete several questionnaires and a follow up phone call.
Recruiting
Has No Placebo
St. Paul's Hospital (+1 Sites)Janny Ke, MDCloud DX Inc.
Image of RUSH University Medical Center in Chicago, United States.

Thrombolysis/Thrombectomy for Deep Vein Thrombosis

18 - 75
All Sexes
Chicago, IL
The goal of this study is to fill the paucity of second line endovascular treatment for acute deep venous thrombus (DVT) by using catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT) as adjunctive second-line treatments for acute DVT patients who show no improvement after an initial anticoagulation trial for one week. The main questions the study aims to answer are: \- Are adjunctive use of endovascular interventional treatments as second-line to DVT treatment safe and efficient? Participants will be followed with repeat US at 1 week after initial DVT to assess for response to anticoagulation treatment. If there is significant residual thrombus with minimal or no response to treatment, participants will be offered enrollment to the study in the office or inpatient setting. Enrolled participants will be randomized into control or intervention arms with 1:1 ratio. Researchers will compare follow-up Villalta and Marder scores between groups to see whether endovascular interventions are safe and efficient.
Phase 4
Waitlist Available
RUSH University Medical CenterBulent Arslan, MD
Have you considered Lonox clinical trials? We made a collection of clinical trials featuring Lonox, we think they might fit your search criteria.Go to Trials
Have you considered Lonox clinical trials? We made a collection of clinical trials featuring Lonox, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security